Quetiapine and aripiprazole appear to be the most robust evidence-based options for augmentation therapy in patients with treatment-resistant depression, but clinicians should interpret these findings cautiously in light of the evidence of potential treatment-related side effects.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: